Map Pharma gains $20M milestone on NDA acceptance; Aspinall to run Ventana Medical Systems;

@FierceBiotech: Teva's oral MS drug trips (again) in blockbuster Ph3 development race. News | Follow @FierceBiotech

@JohnCFierce: Insmed down 30% on the clinical hold. Just illustrates how dicey it is in drug development. | Follow @JohnCFierce

@RyanMFierce: Sequencing giant BGI shoots for the cloud, look out Complete Genomics? Item | Follow @RyanMFierce

@MaureenFierce: Celgene, Alcon, P&G, CSL rank in Forbes' Top 100 Innovative Companies list. Not many life science companies on there. Article | Follow @MaureenFierce

> The FDA has accepted Map Pharmaceuticals' NDA for Levadex, a migraine drug, triggering a $20 million milestone from Allergan. Release

> Mara Aspinall has been named president of Ventana Medical Systems. Aspinall was most recently president, and CEO of On-Q-ity, a start-up diagnostics company focused on circulating tumor cell technology. Release

> Actelion says its MS drug ponesimod looked promising in a Phase IIb dose-finding study, demonstrating a reduction in the number of new active inflammatory lesions in the brain. Release 

> Protalix has formally reapplied for FDA approval of its Gaucher's drug. Story

> The EU has approved AstraZeneca's Axanum, a combination of aspirin and the active ingredient for Nexium. News

> SeraCare Life Sciences has put itself up for sale. Item

> Joe Herring, the CEO of Covance, says that any rival CRO expanding through mergers is likely to face some big integration challenges. Report

Pharma News

@FiercePharma: Add another state AG to the list of Risperdal plaintiffs. Now it's Mass. claiming J&J's marketing crossed the line. News | Follow @FiercePharma

> Another AG sues J&J over Risperdal marketing. Story

Biotech Research News

> US gives out $5M for antiradiation drugs in case of attack. Item

> Leukemia drug helps reverse tamoxifen resistance in breast cancer. News

> A transcriptional time machine may turn back the clock on leukemia. Article

> Genes help personalized stomach cancer treatments. Report

> Of mice, men, sex, and violence. Story

> Nicotine eyed as Parkinson's treatment. More

Manufacturing News

> How an ops driving lesson may have saved former Pfizer CEO Kindler. More

> Genzyme supplies rise, but Fabrazyme lags. News

> Shippers organize air cargo to win over pharma. Story

> UN: Pharma CMOs fare well in investment by developing countries. Article

> Compounding pharmacies shine during drug shortages. Report

And Finally... New research has demonstrated that nicotine can guard the brain against Parkinson's disease. "This study raises the hope for a possible neuroprotective treatment of patients at an early step of the disease or even before at a stage where the disease has not been diagnosed according to motor criteria," said Patrick P. Michel, co-author of the study from the Institut du Cerveau et de la Moelle Épinière, Hôpital de la Salpêtrière, in Paris, France. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.